Sanofi Ends Partnered STAT6 Degrader Program

Previously missed November 3 primary disclosure: Sanofi decided to stop the Phase 1 trial and terminate SAR448272, an oral STAT6 degrader licensed from Nurix. The cause was not given in the issuer announcement; the…





